A Case for Randomized, Double-Blinded, Sham-Controlled Class III Medical Device Trials
(Megan Wright)
Yale Law & Policy Review
(2016)
In this paper, I evaluate the ethical implications of the FDA’s move to en-courage randomized, double-blinded, sham-controlled trials for Class III devices when such studies are possible. In Part I, I describe the placebo effect ...